Article

FCS Advancing Therapies for Patients Through Clinical Research in Community Oncology Practices

Florida Cancer Specialists & Research Institute provides the newest cancer therapies, some not yet available elsewhere, through convenient access to clinical trials.

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly 3 decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations, providing the newest cancer therapies, some not yet available elsewhere, through convenient access to clinical trials.

This is possible through FCS' long-standing partnership with Sarah Cannon—a trusted expert in the field of oncology research having conducted more than 500 first-in-human trials and been a clinical trial leader in the majority of approved cancer therapies over the last decade.

Since the inception of our research program, 10,000 patients have participated in innovative studies.

Learn more.

Related Videos
Mike Fazio, Navista, Cardinal Health
Dr Kimlin Tam Ashing
Andrew Kuykendall, MD, Moffitt Cancer Center
John Michael O'Brien, PharmD, MPH
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo